AKT1 and non-small cell lung carcinoma: The activation of the p53 signaling pathway and the inhibition of RAS-Raf-ERK and PI3K/AKT, which are crucial for the survival of tumor cells, might be the reason why celecoxib combined with metformin exerts a good antitumor effect in NSCLC (Figure 9).